# US 12,214,189 B2 · Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,214,189 B2
- Document ID: US12214189B2
- Status: Granted
- Kind: B2
- Application number: 16/938,778
- Filed: 2020-07-24
- Published: 2021-01-28
- Granted: 2025-02-04
- Earliest claimed: 2019-07-24
- Assignees: Virginia Tech Intellectual Properties, Inc.; Angio Dynamics, Inc.
- Applicants: Virginia Tech Intellectual Properties, Inc.; Angio Dynamics, Inc.
- Inventors: Melvin F. Lorenzo; Christopher B. Arena; Suyashree Bhonsle; Natalie White; Lucy Epshteyn; Rafael V. Davalos
- Web page: https://patentgrep.com/patent/US12214189B2

## CPC

- A61N 1/08: Arrangements or circuits for monitoring, protecting, controlling or indicating {(for external stimulators A61N1/3603; for implantable neurostimulators A61N1/36128; for heart stimulators A61N1/37; for defibrillators A61N1/3925)}
- A61B 18/12: by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B 18/1206: {Generators therefor}
- A61N 1/327: {for enhancing the absorption properties of tissue, e.g. by electroporation}
- A61B 2017/00039: {Electric or electromagnetic phenomena other than conductivity, e.g. capacity, inductivity, Hall effect}
- A61B 2017/0019: {Means for setting or varying the pulse width}
- A61B 2018/00613: {Irreversible electroporation}
- A61B 2018/00642: {with feedback, i.e. closed loop control}
- A61B 2018/00702: {Power or energy}
- A61B 2018/00708: {switching the power on or off}
- A61B 2018/00761: {Duration}
- A61B 2018/00791: {Temperature}
- A61B 2018/00875: {Resistance or impedance}
- A61B 2018/124: {switching the output to different electrodes, e.g. sequentially}
- A61B 2018/143: {multiple needles}
- A61N 2001/083: {Monitoring integrity of contacts, e.g. by impedance measurement}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Electroporation-based therapies (EBTs) employ high voltage pulsed electric fields (PEFs) to permeabilize tumor tissue, resulting in changes in passive electrical properties detectable using electrical impedance spectroscopy (EIS). Currently, commercial potentiostats for EIS are limited by impedance spectrum acquisition time (˜10 s); this timeframe is much larger than pulse periods used with EBTs (˜1 s). Fourier Analysis SpecTroscopy (FAST) is introduced as a methodology for monitoring tissue inter-burst impedance (diagnostic FAST) and intra-burst impedance (therapeutic FAST) during EBTs. FAST is a rapid-capture (<<1 s) technique which enables monitoring of inter-burst and intra-burst impedance during EBTs in real-time. FAST identified a frequency which delineates thermal effects from electroporation effects in measured impedance. Significance: FAST demonstrates the potential to perform EIS, in addition to intra-burst impedance spectroscopy, using existing pulse generator topologies.

## Claims

### Claim 1

A method for monitoring administration of electrical pulses comprising:
administering a plurality of electrical pulses to a material or a tissue;
obtaining a reference impedance measurement or spectrum relating to the material or tissue;
identifying any change in impedance relative to the reference impedance measurement or spectrum by measuring inter-burst and intra-burst impedance; and
monitoring the administering to determine if a desired endpoint is reached as indicated by the change in impedance, and i) adjusting one or more parameters of, ii) stopping, iii) halting, and/or iv) continuing the administering based on the monitoring.

### Claim 2 (depends on 1)

The method of claim 1, wherein the desired endpoint is a point during the administering where the administering of the electrical pulses no longer contributes to any change in impedance.

### Claim 3 (depends on 1)

The method of claim 1, wherein the reference impedance measurement is:
a prior low-frequency impedance measurement or spectrum; or
a reference high-frequency impedance measurement or spectrum.

### Claim 4 (depends on 3)

The method of claim 3, wherein the desired endpoint is a point where the impedance measurement or spectrum decreases to a value within:
20% of the reference high-frequency impedance measurement or spectrum; or
0-10% of the prior low-frequency impedance measurement or spectrum.

### Claim 5 (depends on 3)

The method of claim 3, wherein the administering comprises applying one or more low-voltage pulses interleaved between one or more high-voltage pulses.

### Claim 6 (depends on 1)

The method of claim 1, further comprising halting the administering to allow tissue temperature to reach a desired level or to allow for a selected amount of time to pass, then resuming the administering to the desired endpoint.

### Claim 7 (depends on 1)

The method of claim 1, wherein:
delivering a low-voltage, wideband signal of electrical pulses; and
the monitoring comprises monitoring inter-burst, intra-burst, intra-pulse, and/or inter-pulse impedance by capturing voltage and current and performing discrete Fourier transform analysis.

### Claim 8 (depends on 7)

The method of claim 7, wherein the signal comprises a waveform with any step, square, sinusoidal, ramp, Gaussian, or sinc function having constant, increasing, or decreasing frequency, or any arbitrary signal designed to achieve a desired frequency spectrum in the range of above 0.1 kHz to 100 MHz.

### Claim 9 (depends on 7)

The method of claim 7, wherein the delivering comprises applying pulses in the range of 0.1 μs to 10 ms.

### Claim 10 (depends on 7)

The method of claim 7, wherein the delivering comprises administering the electrical pulses using a cycled pulsing protocol whereby pairs of electrodes are activated according to a selected sequence until a desired number of electrical pulses is delivered.

### Claim 11 (depends on 1)

The method of claim 1, wherein:
the administering comprises delivering one or more high-voltage bursts of pulsed electric fields; and
the monitoring comprises monitoring tissue response through monitoring high-voltage inter-pulse, intra-pulse, intra-burst, and/or inter-burst impedance by capturing voltage and current and performing discrete Fourier transform analysis.

### Claim 12 (depends on 1)

The method of claim 1, wherein the reference impedance measurement or spectrum and/or measured impedance is obtained by:
reference to an impedance spectrum based on standard impedance values for a particular material or tissue;
measuring impedance of a material or tissue over a selected frequency band;
measuring voltage and/or current and calculating impedance therefrom; and/or
calculating impedance as a function of frequency using the formula:
Z
⁡
(
f
)
=
V
⁡
(
f
)
I
⁡
(
f
)
,
wherein: Z is impedance; V is voltage; and I is current.

### Claim 13 (depends on 1)

The method of claim 1, further comprising using a change in impedance measured at high frequencies to predict temperature change for the administering.

### Claim 14 (depends on 1)

The method of claim 1, wherein the change in impedance indicates:
whether irreversible or reversible electroporation of a tissue has, is or will occur;
whether chemical cell death and/or decellularization has, is or will occur;
whether death and/or decellularization has, is or will occur due to a physical disruption;
whether a tissue is healthy or cancerous;
whether a tissue has damage from a stroke and/or traumatic brain injury;
whether cell lysis has, is or will occur as evidenced by flattening of the impedance spectrum with no recovery following pulse cessation;
whether cell necrosis has, is or will occur as evidenced by flattening of the impedance spectrum with minimal recovery following pulse cessation; and/or
whether cell apoptosis has, is or will occur as is evidenced by flattening of the impedance spectrum with moderate recovery following pulse cessation.

### Claim 15 (depends on 1)

The method of claim 1, wherein the monitoring comprises:
monitoring tissue decellularization and/or cell death;
monitoring gene-transfection efficiency and uptake;
monitoring thermal and/or non-thermal tissue ablation for cardiac arrythmias; and/or
monitoring cell lysis for immunotherapies.

### Claim 16 (depends on 1)

The method of claim 1, wherein the administering comprises a diagnostic pulsing scheme comprising 50-100 cycles of 1-50-1-50 μs pulsing and 1-5 cycles of 250-10-250-10 μs pulsing.

### Claim 17 (depends on 1)

The method of claim 1, wherein the administering comprises 10-50 cycles of a pulsing scheme chosen from:
1-5-1--100 μs,
5-5-5--100 μs,
10-5-10--100 μs,
2-1-2--100 μs,
2-10-2--100 μs,
2-100-2--100 μs,
2-5-2--1 μs,
2-5-2--10 μs, or
2-5-2--100 μs.

### Claim 18

A method for monitoring administration of electrical pulses comprising:
administering high-voltage bursts of electrical pulses to a material or a tissue using a high-frequency irreversible electroporation burst scheme;
obtaining a reference impedance measurement or spectrum relating to the material or tissue;
identifying any change in impedance, at a frequency in the range of 18.3 kHz to 2 MHZ, relative to the reference impedance measurement or spectrum;
monitoring tissue response to the administering by monitoring high-voltage inter-pulse, intra-pulse, intra-burst, and/or inter-burst impedance by capturing voltage and current and performing discrete Fourier transform analysis to determine if a desired endpoint is reached as indicated by the change in impedance; and
adjusting one or more parameters of, stopping, halting, and/or continuing the administering based on the monitoring;
wherein the high-frequency irreversible electroporation burst scheme comprises pulse widths and intra-phase delays ranging from 0.1 μs to 10 ms and inter-pulse delays ranging from 0.1 μs to 1 s.